Adimab has congratulated GSK for recently receiving approvals by the European Commission (EC) and China's National Medical Products Administration (NMPA) for depemokimab. This adds to recent marketing approvals in the US, Japan, and the UK.

Depemokimab is the first ultra-long-acting biologic product approved for use in its indicated conditions and was developed internally by GSK with an extended half-life and engineered high-binding affinity to enable twice-yearly dosing, as demonstrated in GSK's pivotal trials.

To support in the engineering of the molecule, GSK internalised Adimab's proprietary yeast-based technology, enabling in-house antibody discovery, optimisation, production, and characterisation on any target of GSK's choosing. GSK's research team used the Adimab Platform for depemokimab, a product tailored to meet GSK's target product profile, including low picomolar affinity.

GSK continues to use the Adimab platform to support other internal programs.

"Depemokimab is the first approved product to emerge from our Platform Transfer collaborations, further validating this portion of our business model. Fittingly, GSK was our first Platform Transfer collaborator, and we congratulate them on this tremendous success," said Philip T. Chase, Chief Executive Officer, Adimab.

Adimab's other Platform Transfer collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda. Each Platform Transfer collaborator has been enabled, through training at Adimab and their own site, to operate Adimab's proprietary platform independently. Further, each Platform Transfer collaborator has their own unique diversity, ensuring non-overlapping outputs. The Adimab technology can be used on any biologic target, in any format, and in any therapeutic area, allowing flexibility from discovery through engineering and generation of multispecifics. Support is always available, including access to Adimab scientists, biannual technology summits, and regular updates to strains, libraries, and in-silico tools.

"Depemokimab is just one example of GSK's adoption of the Adimab technology to pursue innovative therapeutic products," added Eric Krauland, President and Chief Scientific Officer, Adimab. "GSK's use of the platform, exemplified through ongoing investment in the Adimab team's expertise and the use of Adimab's technological advances such as new library diversities, has translated into other GSK clinical programs that aim to make a real difference for patients."